Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00163111
NCT00163111CompletedPhase 3

A Randomized, Open Label, Comparative Multicenter Study Of Voriconazole Versus Conventional Amphotericin B Followed By Fluconazole In The Treatment Of Candidaemia In Non Neutropenic Subjects.

Pfizer0 sites412 target enrollmentStarted: September 1, 1998Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Pfizer
Enrollment
412
Primary Endpoint
Sustained clinical response for 12 weeks from end of treatment
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a study to investigate the safety and efficacy of voriconazole for the treatment of candidemia in critically ill non-neutropenic patients

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with candidemia

Exclusion Criteria

  • •Neutropenia

Outcomes

Primary Outcomes

Sustained clinical response for 12 weeks from end of treatment

Secondary Outcomes

  • Time to negative blood cultures

Investigators

Sponsor
Pfizer
Sponsor Class
Industry

Similar Trials

Completed
Phase 3
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal InfectionsFungemiaMycosesCandidiasisAspergillosis
NCT00001810National Cancer Institute (NCI)300
Completed
Phase 2
Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary AspergillosisAllergic Bronchopulmonary Aspergillosis
NCT01621321Post Graduate Institute of Medical Education and Research, Chandigarh50
Terminated
Phase 3
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric PatientsCandidiasis
NCT01092832Pfizer23
Terminated
Phase 3
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In ChildrenInvasive Aspergillosis
NCT00836875Pfizer31
Completed
Phase 3
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated DiarrheaClostridium Difficile Infection
NCT01983683Actelion631